CALT / Calliditas Therapeutics: Good Long-Term Data Could Boost Tarpeyo Sales

STOCKHOLM , Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven ab more_horizontal

Calliditas Therapeutics AB Sponsored ADR (CALT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earn more_horizontal

Calliditas' lead therapy is Tarpeyo, which has accelerated approval from the FDA to fight a rare autoimmune disease affecting the kidney. The company more_horizontal

Calliditas Therapeutics downgrades Tarpeyo sales guidance due to slower-than-expected sales growth and market access challenges. Potential growth driv more_horizontal

Calliditas (CALT) soars as the supplement new drug application seeking to convert accelerated approval of Tarpeyo delayed-release capsule to full appr more_horizontal

Calliditas Therapeutics AB Sponsored ADR (CALT) saw its shares surge in the last session with trading volume being higher than average. The latest tre more_horizontal

Calliditas Therapeutics recently reported positive long-term data of Tarpeyo (Nefecon/budesonide) in patients with IgA nephropathy. The results confir more_horizontal

STOCKHOLM , March 31, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced its mana more_horizontal